Vaccine plus immunotherapy for prostate cancer that has returned
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of a DNA vaccine (pTVG-HP) and an immunotherapy drug (nivolumab) along with targeted radiation or ablation of remaining cancer spots. It is for men whose prostate cancer has come back after surgery but hasn't spread widely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove your prostate (prostatectomy) and any follow-up radiation was at least 3 months ago.
- Your cancer has returned based on rising PSA levels, and scans show 3 or fewer spots where cancer has spread.
- You have not had hormone therapy for more than 24 months, and your last dose was at least 3 months ago.
- You are generally healthy with good organ function and an ECOG score of 0 or 1.
- You are willing to have blood drawn for research over the next year.
- You do not have other active cancers or serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called IL-15 superagonist (with or without a vaccine) for men whose prostate cancer has come back (shown by rising PSA) after they already had targeted radiation therapy. The goal is to see if this treatment can lower or control PSA levels.
This trial tests a personalized vaccine (FK-PC101) given after prostate removal surgery for men with high-risk prostate cancer. It aims to see if the vaccine can help prevent the cancer from coming back without the need for additional hormone therapy or radiation.
This trial tests an experimental vaccine (2141-V11) combined with standard hormone therapy and an anti-androgen drug before prostate removal surgery. It aims to see if the combination can help the immune system fight the cancer more effectively.
This trial tests a combination of a personalized peptide vaccine and an antibody therapy for men with prostate cancer that has returned after initial treatment. The goal is to see if this approach can control the cancer without needing stronger hormone therapy.
This trial tests a powerful radioactive drug (either alpha or beta) combined with precise radiation to treat prostate cancer that has come back in a few spots outside the prostate. It may help men whose cancer is still hormone-sensitive and has not spread widely.
This study combines two treatments: pembrolizumab, which helps your immune system fight cancer, and a targeted radioactive medicine (177Lu-PSMA-617) that seeks out and damages prostate cancer cells. It may help men whose prostate cancer has spread despite initial hormone therapy.
Hear when a new Prostate Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.